Decision: Favourable

Decisions Table

Study Title:

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  • NREC Code:

    21-NREC-CT-133

  • Decision:

    Favourable

  • Meeting Date:

    17/11/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Ray McDermott

  • PI Institution:

    Tallaght University Hospital

  • Sponsor:

    MSD

Scroll to Top